Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity like teriparatide. Recent data from the phase 3 fracture prevention trial demonstrate that this agent is effective in reducing fracture risk. Inhibiting cathepsin K reduces bone resorption without decreasing the numbers or activity of osteoclasts, thereby preserving or promoting osteoblast function. Progressive increases in bone mineral density (BMD) have been observed over 5 years. Early data suggest that odanacatib effectively reduces fracture risk. Lastly, inhibiting sclerostin with humanized antibodies promotes rapid, substantial but transient increases in bone formation while inhibiting bone resorption. Marked increases in BMD have been observed in phase 2 studies. Fracture prevention studies are underway. The new therapies with novel and unique mechanisms of action may, alone or in combination, provide more effective treatment options for our patients.

Citations

Citations to this article as recorded by  

• The osteocyte as a signaling cell
  Jesus Delgado-Calle, Teresita Bellido
  Physiological Reviews.2022; 102(1): 379.     CrossRef
• Combining sclerostin neutralization with tissue engineering: An improved strategy for craniofacial bone repair
  Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain
  Acta Biomaterialia.2022; 140: 178.     CrossRef
• Effects of sclerostin antibody on bone healing
  Atsushi Mihara, Kiminori Yukata, Toshihiro Seki, Ryuta Iwanaga, Norihiro Nishida, Kenzo Fujii, Yuji Nagao, Takashi Sakai
  World Journal of Orthopedics.2021; 12(9): 651.     CrossRef
• Combining Sclerostin Neutralization with Tissue Engineering:  An Improved Strategy for Craniofacial Bone Repair
  Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain
  SSRN Electronic Journal.2021;[Epub]     CrossRef
• Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
  Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
  Endocrinology and Metabolism.2020; 35(1): 55.     CrossRef
• Clinical Application of Teriparatide in Fracture Prevention
  Yuehong Chen, Ronghan Liu, Aubryanna Hettinghouse, Shuya Wang, Gang Liu, Chuan-ju Liu
  JBJS Reviews.2019; 7(1): e10.     CrossRef
• The Emerging Role of Osteocytes in Cancer in Bone
  Emily G Atkinson, Jesús Delgado‐Calle
  JBMR Plus.2019;[Epub]     CrossRef
• Osteoporosis therapies might lead to intervertebral disc degeneration via affecting cartilage endplate
  Zhen Sun, Zhuo-Jing Luo
  Medical Hypotheses.2019; 125: 5.     CrossRef
• Polymersome nanoparticles for delivery of Wnt-activating small molecules
  Edoardo Scarpa, Agnieszka A Janeczek, Alethia Hailes, Maria C de Andrés, Antonio De Grazia, Richard OC Oreffo, Tracey A Newman, Nicholas D Evans
  Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(4): 1267.     CrossRef
• Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects
  Jing Wu, Qi Shen, Wei Cui, Yu Zhao, Yue Huai, Yu-chao Zhang, Bei-hua Bao, Chen-xi Liu, Qing Jiang, Jian-xin Li
  Acta Pharmacologica Sinica.2018; 39(2): 230.     CrossRef
• Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
  Chee Kian Chew, Bart L. Clarke
  Maturitas.2017; 97: 53.     CrossRef
• Dried and free flowing granules of Spinacia oleracea accelerate bone regeneration and alleviate postmenopausal osteoporosis
  Sulekha Adhikary, Dharmendra Choudhary, Naseer Ahmad, Sudhir Kumar, Kapil Dev, Naresh Mittapelly, Gitu Pandey, Prabhat Ranjan Mishra, Rakesh Maurya, Ritu Trivedi
  Menopause.2017; 24(6): 686.     CrossRef
• Romosozumab for the treatment of osteoporosis
  Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian
  Expert Opinion on Biological Therapy.2017; 17(2): 255.     CrossRef
• The quest for new drugs to prevent osteoporosis-related fractures
  T. J. de Villiers
  Climacteric.2017; 20(2): 103.     CrossRef
• Role and mechanism of action of sclerostin in bone
  Jesus Delgado-Calle, Amy Y. Sato, Teresita Bellido
  Bone.2017; 96: 29.     CrossRef
• Biochemical Testing Relevant to Bone
  Chee Kian Chew, Bart L. Clarke
  Endocrinology and Metabolism Clinics of North America.2017; 46(3): 649.     CrossRef
• Re-Invigorating the Osteoporosis Message
  Michael R. McClung
  Endocrine Practice.2016; 22(9): 1130.     CrossRef
• Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis
  Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian
  Expert Opinion on Drug Metabolism & Toxicology.2016; 12(6): 681.     CrossRef
• Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
  Michael Pazianas, Bo Abrahamsen
  Annals of the New York Academy of Sciences.2016; 1376(1): 5.     CrossRef
• Anti-senescence and Anti-inflammatory Effects of the C-terminal Moiety of PTHrP Peptides in OA Osteoblasts
  Julia Platas, Maria Isabel Guillén, Francisco Gomar, Miguel Angel Castejón, Pedro Esbrit, Maria José Alcaraz
  The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2016; : glw100.     CrossRef
• Osteocytic signalling pathways as therapeutic targets for bone fragility
  Lilian I. Plotkin, Teresita Bellido
  Nature Reviews Endocrinology.2016; 12(10): 593.     CrossRef